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Subpopulations of nasopharyngeal carcinoma (NPC) contain cells with differential tumourigenic 
properties. Our study evaluates the tumourigenic potential of CD24, CD44, EpCAM and combination of 
EpCAM/CD44 cells in NPC. CD44br and EpCAMbr cells enriched for higher S-phase cell content, faster-
growing tumourigenic cells leading to tumours with larger volume and higher mitotic figures. Although 
CD44br and EpCAMbr cells significantly enriched for tumour-initiating cells (TICs), all cells could retain 
self-renewal property for at least four generations. Compared to CD44 marker alone, EpCAM/CD44dbr 
marker did not enhance for cells with faster-growing ability or higher TIC frequency. Cells expressing 
high CD44 or EpCAM had lower KLF4 and p21 in NPC subpopulations. KLF4-overexpressed EpCAMbr 
cells had slower growth while Kenpaullone inhibition of KLF4 transcription increased in vitro cell 
proliferation. Compared to non-NPC, NPC specimens had increased expression of EPCAM, of which 
tumours from advanced stage of NPC had higher expression. Together, our study provides evidence that 
EpCAM is a potentially important marker in NPC.
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer predominantly found in the southern 
Chinese population, several indigenous groups of the Southeast Asia, Amazigh- and Arabic-speaking popula-
tions of North Africa, and the Inuits of North America and Greenland1. It is infamously associated with high die-
tary intake of salted and/or preserved food, exposure to tobacco and formaldehyde as well as Epstein-Barr virus 
(EBV) infection1. Although it is a highly radiosensitive malignancy, its initial nonspecific clinical presentations 
such as nasal blockage, blood-tainted sputum, ringing in the ears and mild hearing loss are the main obstacles to 
early diagnosis2,3 and the 5-year overall survival rate for NPC patients can reduce remarkably in late-stage of the 
disease4.
Studies on NPC tumour biology such as growth, stemness, invasion, metastasis, therapy resistance and EBV 
presence have been widely investigated mainly using NPC cell lines. Stem-like cells from NPC cell lines were 
commonly enriched by using functional assays such as the side population (SP) assay5–7, spheroid assay8 and 
ALDH assay9. The SP cells in frequently used CNE-2 and HK1 cell lines were found to be more tumour-inducing 
in nude mice than bulk cells6,7. Cells from another NPC cell line, C666-1 which grew as free-floating spheres, 
displayed stemness characteristics such as a propensity for tumour formation, contained higher expression levels 
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of pluripotent genes SOX2 and KLF4 as well as metastasis-associated gene CD44 than the normally adherent ones, 
and had higher tumourigenic potential in vivo8. ALDH1 positive cells from 5-8F and CNE-2 cell lines induced 
tumour growth, contained higher percentage of SP subpopulation and had higher levels of OCT4, BMI1, KLF4 
and SOX2 transcripts than ALDH1 negative cells9.
As cancer cells from patient samples are made up of heterogeneous cell types potentially with different tum-
origenic ability, the use of surface markers have aided in the isolation of these cells directly from clinical samples 
for the study of their roles in tumourigenesis10,11. These markers which are largely associated with tumour growth, 
metastasis and survival are commonly referred to as cancer stem cell (CSC) markers. There is a dearth of such 
studies using clinical samples in NPC due to sample size limitation as surgery is not the mainstay treatment 
modality12,13.
Based on the latest reviews on CSC markers in NPC cell lines, CD44, an extracellular receptor for hyaluronan, 
seems to be the most widely studied marker with roles ranging from tumour initiation, cell proliferation and 
differentiation to 5-fluorouracil treatment resistance14,15. In breast and rat mammary carcinomas, CD24 is known 
as a marker for metastasis due to its binding to P-selectin which facilitated the passage of tumour cells in the 
bloodstream during metastasis16,17. The absence or low expression of CD24 is synonymous with identifying breast 
CSCs as was first highlighted by Al-Hajj et al.18. EpCAM (CD326) or previously known as ESA (epithelial specific 
antigen) functions as an epithelial-specific intercellular cell adhesion molecule with additional involvement in 
cellular signalling, cell migration, proliferation and differentiation19. It identified cancer cells with tumourigenic 
and stem-like properties in combination with CD24, CD44 and/or CD166 in breast, lung and gastric carcino-
mas18,20,21. Not much is known, however, regarding EpCAM in NPC.
To the best of our knowledge, the roles of CD24, CD44 and EpCAM in NPC tumourigenesis have not been 
evaluated within the same cell populations in cell lines or patient-derived xenografts (PDXs). Due to its close 
resemblance to clinical samples, early-passage PDXs have been advocated to be used as study models for tumour 
heterogeneity, CSCs and therapy-related studies, instead of cell lines22–25. However, most NPC biological studies 
were performed on NPC cell lines which have been in passage for many generations8,26,27 or primary culture 
derived xenograft28,29, some with questionable authenticity and/or origin as were reported for CNE-1, CNE-2 
and HONE-130,31. Most importantly, the gold standard for evaluation of CSCs32,33 i.e. in vivo serial transplantation 
assay was not used to thoroughly assess self-renewal ability in aforementioned studies on NPC stem-like cells.
In the present study, we evaluated the expression of CD24, CD44 and EpCAM in a set of NPC samples com-
prising of two cell lines (HK1 and C666-1) and two early-passage PDXs (xeno-284 and xeno-B110) by flow 
cytometry analysis. Subsequently, CD24, CD44, EpCAM and EpCAM/CD44 marker-selected subpopulations 
were isolated from C666-1 and xeno-B110. These cells were characterized for tumour initiation, growth abil-
ity and tumour-initiating cell (TIC) frequency. In addition, selected cells were examined for self-renewal by 
serial-transplantation for four generations, gene and protein expressions related to stemness, pluripotency, pro-
liferation and cell cycle. Finally, proliferation-related activity of KLF4 was examined in xeno-B110, and expression 
of selected mRNA and proteins were assessed in NPC specimens.
Results
NPC cell lines and PDXs display variable expression of common surface markers. As CD24, 
CD44 and EpCAM were frequently used to isolate tumourigenic cells18,21,25,34,35, their expression levels were 
assessed in NPC cell lines (HK1 and C666-1 cell lines) and early-passage PDXs (xeno-284 and xeno-B110) by 
flow cytometry (Fig. 1). Xeno-284 and xeno-B110 are two NPC PDXs newly established in our lab. Prior to 
use, HK1 and C666-1 cells were authenticated by STR profiling and found to be identical and closely related, 
respectively, to the ones used by NPC researchers30 (Supplementary Table S1). Periodical tests showed that both 
cell lines were mycoplasma-free. STR data also verified that xeno-284 and xeno-B110 show a high concordance 
to the original NPC patients’ blood samples and are different from known NPC PDXs such as xeno-666, C15 or 
C17 (Supplementary Table S1). EBV status in in xeno-B110 and xeno-284 was verified by EBER-ISH method 
(Supplementary Fig. S1).
Figure 1. Expression of common surface markers in NPC cell lines and NPC xenografts. Percentage of marker 
positive cells from the cell lines were counted from the total number of single, viable cells. As for the xenografts, 
the denominator was total number of single, viable, non-mouse cells. Results, mean ± SD of 3 flow cytometry 
experiment replicates.
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CD24 was highest in xeno-B110 (85.37 ± 10.51% positive cells), moderately expressed in xeno-284 and HK1 
(55.33 ± 14.17% and 62.77 ± 14.63%, respectively), and extremely low to absent (0.00 ± 0.06%) in C666-1 (Fig. 1). 
Absence of CD24 expression was also observed in C666-1 cells passaged in vivo (“xeno-C666-1”) (Supplementary 
Fig. S2). CD44 was moderate to highly expressed in all samples with the lowest level in xeno-B110 (70.15 ± 3.23%) 
and the highest in HK1 (99.47 ± 0.15%) (Fig. 1). More than 95% EpCAM positivity was detected in all samples 
except for xeno-B110 (75.79 ± 12.45%) (Fig. 1).
NPC is prevalently EBV positive, hence subsequent experiments were performed using EBV positive C666-1 
and xeno-B110 samples derived from primary NPC specimens, as opposed to EBV negative HK1 and xeno-284 
which were established from recurrent NPC specimens. Also, as the negative subpopulations of CD24, CD44, 
EpCAM and EpCAM/CD44 were scarce in C666-1 and xeno-B110, bright and dim phenotypes of each marker 
were studied for their biological properties (Supplementary Fig. S3). Marker bright and dim phenotypes were 
isolated according to the gating strategy as described in Supplementary Methods. A sample of the gating strategy 
is exemplified in Supplementary Fig. S4. The overall in vitro and in vivo work flow is explained in Supplementary 
Fig. S5.
Bright phenotype of CD44 and EpCAM select for rapid growing NPC cells resulting in the forma-
tion of larger xenografts. Owing to an extremely low level of CD24 positive cells in C666-1 (Fig. 1), only 
CD44, EpCAM and EpCAM/CD44-selected cells from C666-1 were evaluated for their tumour-initiating ability 
in NSG mice. At an inoculation of 2,000 cells, all marker-selected C666-1 cells initiated 100% tumour formation 
(5/5) except for CD44dim (80%, 4/5) (Supplementary Table S2). CD44br cells significantly induced faster growth 
with a mean latency of 35.60 ± 1.50 days in contrast to CD44dim cells with a longer mean latency of 44.80 ± 6.85 
days (p < 0.05) (Supplementary Table S2). Growth curve of CD44br-induced tumours was indicative of higher 
proliferation rate compared to the growth curve of CD44dim-induced tumours (Fig. 2ai). The mean adjusted 
mitotic activity index (MAI) for CD44br tumours was 124.20 ± 15.58 compared to 94.80 ± 39.47 for CD44dim 
tumours (Fig. 2aiii). Differences in mean latency data and growth curves were less apparent between EpCAMbr 
and EpCAMdim tumours (Supplementary Table S2, Fig. 2bi) but the significantly lower mean adjusted MAI in 
EpCAMdim tumours (p = 0.0299) was still observed (Fig. 2biii).
As xeno-B110 is a NPC PDX newly established in our lab, a pilot experiment was performed to determine 
its tumour-forming ability with a titration of cell inoculation numbers (Supplementary Table S3). Host mouse 
cells (H2Kd positive) was removed by cell sorting and only viable non-mouse cells (H2Kd negative or “parental 
xeno-B110 cells”) were inoculated. There was a near 100% tumour formation from 100,000 to 500 cell inocu-
lations (except for 5,000 cell inoculation). Tumour formation was greatly reduced at 100 cell inoculation (2/6; 
33.33%) with no tumour at 10 cells (0/6; 0%). At 2,000 cell inoculation with marker-sorted cells, there was 
100% tumour initiation (5/5 or 4/4) in all groups of cells except for CD44dim (60%, 3/5) and EpCAMdim (80%, 
4/5) (Supplementary Table S4). Cell cycle analysis on fixed freshly-sorted cells showed that the percentage of 
S-phase cells were not significantly different between CD24br cells and CD24dim cells (Fig. 3ai). However, a 
4-day shorter mean latency and slightly higher growth rate was observed in CD24br compared to CD24dim 
xenografts (Supplementary Table S4 and Fig. 3aii) which corresponded with a visible difference in mean adjusted 
MAI values within CD24 xenografts (Fig. 3aiv). CD44br cells contained 13.26 ± 1.56% of S-phase cells which 
were significantly higher compared to CD44dim cells which only had 4.41 ± 0.47% of S-phase cells (p < 0.01) 
(Fig. 3bi). The significant difference of mean latency between CD44br and CD44dim xenografts was 6.4 days 
(Supplementary Table S4). CD44br xenografts were larger and contained higher adjusted MAI than CD44dim 
xenografts (Fig. 3biii–iv). Similar to CD44br cells, EpCAMbr cells had significantly higher presence of S-phase 
cells (12.43 ± 2.77%) compared to EpCAMdim cells (5.06 ± 0.33%), a significant 8.6 days shorter mean latency, 
faster growth rate and higher adjusted MAI than EpCAMdim cells/xenografts (Supplementary Table S4, 
Fig. 3ci–iv).
Overall in both C666-1 and xeno-B110 cells, CD44br and EpCAMbr markers seemed to be consistently 
enriching for faster-growing cells. In order to investigate whether combination of CD44 and EpCAM markers 
may further enrich for faster-growing cells, C666-1 and xeno-B110 cells with double bright phenotype of EpCAM 
and CD44 (EpCAM/CD44dbr) were evaluated for their growth properties. Mean latency, growth curve and 
adjusted MAI’s differences were less discerning between EpCAM/CD44dbr and EpCAM/CD44ddim tumours 
from C666-1 (Supplementary Table S2, Fig. 2c). In xeno-B110, EpCAM/CD44dbr cells had 14.77 ± 4.15% of 
S-phase cells compared to EpCAM/CD44ddim cells which only had 3.22 ± 0.47% (p = 0.0425) (Fig. 3di). A sig-
nificant 8.8 days difference in mean latency data was observed between EpCAM/CD44dbr cells and EpCAM/
CD44ddim cells (Supplementary Table S4). A very obvious difference between the growth curves of EpCAM/
CD44dbr and EpCAM/CD44ddim xenografts and the sizes of harvested xenografts were observed (Fig. 3dii–iii). 
However, there was no difference in the mean adjusted MAI between EpCAM/CD44dbr (169.20 ± 24.22) and 
EpCAM/CD44ddim (163.60 ± 26.51) xenografts (p = 0.8799) (Fig. 3div). Taken together, our data indicated that 
EpCAM/CD44dbr combination marker did not identify for a substantial increase of faster-growing cells than 
CD44br or EpCAMbr marker alone in C666-1 and xeno-B110.
Significant enrichment of tumour-initiating cells (TICs) by CD44 and EpCAM in the first genera-
tion of xeno-B110. CD24br cells had a slight increase (1.79 folds) of TICs compared to CD24dim cells but it 
was not statistically significant (p = 0.42) (Table 1). CD44br and EpCAMbr cells were significantly more enriched 
in TICs than their respective dim phenotypes (17.49 folds at p < 0.001 and 4.97 folds at p = 0.01, respectively) 
(Table 1). The significant enrichment in TIC frequency was also observed in EpCAM/CD44dbr cells (8.25 folds at 
p < 0.01). However, it is noted that the enrichment fold of double bright markers did not exceed the one by single 
CD44br marker alone (Table 1).
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CD24, CD44 and EpCAM marker-sorted xeno-B110 cells retain self-renewal property during 
serial transplantation in vivo. An in vivo serial transplantation assay was performed using CD24, CD44 
and EpCAM-selected cells from xeno-B110 to determine if they were able to self-renew by initiating new tumours 
up to the fourth generation. All groups were re-sorted for respective phenotype of cells before re-inoculation 
into recipient mice as secondary/tertiary/quartenary xenografts. All phenotypes could self-renew for at least 
four generations although with different TIC frequencies (Table 2) while maintaining similar histology of 
Figure 2. Growth properties of CD44, EpCAM and EpCAM/CD44 cells from C666-1. Growth curve (i), image 
(ii) and adjusted MAI (iii) of the harvested xenografts for (a) CD44, (b) EpCAM and (c) EpCAM/CD44. Results 
of growth curve, mean ± SEM of 5 tumour replicates. m, rate of volume increase. Red circle in (aii) indicates a 
fat tissue and is considered as “no tumour”. *p < 0.05
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non-keratinizing differentiated NPC as the parental xeno-B110 cells (Supplementary Fig. S6). Upon serial trans-
plantation at the fourth generation, CD24br cells appeared to have the highest enrichment of TICs (10.55 folds), 
followed by CD44br and EpCAMbr cells (7.07 and 4.89 folds, respectively) (Table 2).
Figure 3. Growth properties of CD24, CD44, EpCAM and EpCAM/CD44 cells from xeno-B110. Cell cycle 
profile of freshly-sorted fixed cells (i), growth curve (ii), image (iii) and adjusted MAI (iv) of the harvested 
xenografts for (a) CD24, (b) CD44, (c) EpCAM and (d) EpCAM/CD44. Results of cell cycle profile, mean ± SD 
of 3 or 4 flow cytometry experiment replicates. *p < 0.05 (S-phase), **p < 0.01 (S-phase). Results of growth 
curve, mean ± SEM of 4 or 5 tumour replicates. m, rate of volume increase. X, mouse died immediately after 
inoculation.
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CD24, CD44, and EpCAM-sorted xeno-B110 cells display differentially expressed genes and 
proteins. Expression of 21 genes was measured in freshly-sorted xeno-B110 cells: three housekeeping genes, 
three genes coding for surface markers used in this study, 15 genes associated with stemness, pluripotency, pro-
liferation and cell cycle (Supplementary Table S5, Fig. 4). As expected, CD24br cells had higher CD24 mRNA 
transcripts than CD24dim cells, CD44 mRNA was more than 2-fold enriched in CD44br cells compared to 
CD44dim cells, whereas the levels of EPCAM mRNA transcripts in EpCAMbr cells were increased approximately 
4 folds compared to EpCAMdim cells (Fig. 4a). Our data showed that overall the transcript levels of NANOG 
and BMI were higher in EpCAMbr cells compared to EpCAMdim cells (Fig. 4a). Compared to its counterpart, 
both EpCAMbr and CD44br cells had increased levels of MKI67 and OCT4A (Fig. 4a). KLF4 and its downstream 
transcriptional targets CDKN1A (encoding for p21) and CCND1 (encoding for cyclin D1), CCNE1, and VIM 
were found to be differentially expressed in at least one of the marker sorted cells (Fig. 4b). KLF4, CCND1 and 
CDKN1A transcripts were consistently downregulated in EpCAMbr cells compared to their respective dim phe-
notype. CCNE1 level was slightly upregulated only in CD44br cells. Moderate upregulation of VIM was observed 
in CD24br cells. The levels of CTNNB1, MYC and NOTCH1 were not changed in these sorted cells (Fig. 4b). 
LMP1 and LMP2A mRNA transcripts from EBV were below the detection limit in this experiment (Ct > 35), 
although xeno-B110 was EBV positive as evident by positive staining for EBER (Supplementary Fig. S1). The 
scarcity of these two EBV transcripts was verified by RNA-ISH (data not shown).
Downregulation of selected genes in subpopulations of marker-selected xeno-B110 cells was also seen at the 
protein level. The staining of freshly-sorted cytospin cells showed overall lower KLF4 in the bright cells com-
pared to the corresponding dim cells (Supplementary Table S6). Co-staining of individual surface marker with 
KLF4 using immunofluorescence (IF) technique in xeno-B110 also revealed patches of marker bright area with 
low nuclear KLF4 staining, and vice-versa (representative images in Fig. 5, Supplementary Fig. S8). Although 
co-staining of surface markers with p21 or cyclin D1 in xeno-B110 tumour FFPE sections indicated inverse 
expression levels between these two proteins (representative images in Fig. 5), the differential p21 and cyclin D1 
levels were less discerning in freshly-sorted cytospin cells (Supplementary Table S6).
Modulation of KLF4 affects in vitro proliferation of xeno-B110. EpCAMbr cells of xeno-B110 were 
transduced with KLF4 and evaluated for in vitro proliferation for 5 days. KLF4 overexpression was first verified 
Cell 
inoculation 
number
Number of tumours/Number of inoculated mice
H2Kd 
neg
CD24 
br
CD24 
dim
CD44 
br
CD44 
dim
EpCAM 
br
EpCAM 
dim
EpCAM/
CD44dbr
EpCAM/
CD44ddim
xeno-B110
30,000 4/4 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3
10,000 4/4 6/6 6/6 5/5 5/5 5/5 5/5 6/6 6/6
5,000 5/6 5/5 6/6 4/4 4/4 6/6 6/6 5/5 5/5
2,000 ND 5/5 4/4 5/5 3/5 5/5 4/5 5/5 5/5
500 3/3 3/3 3/3 3/3 3/3 3/3 2/3 3/3 2/3
100 2/6 2/6 1/6 5/6 1/6 3/6 2/6 5/6 1/6
10 0/6 1/6 0/6 2/6 2/6 0/6 0/6 1/6 0/6
Estimated 
TIC frequency 
(95% CI)
1 in 
1177 
(393–
3526)
1 in 159 
(63–
404)
1 in 285 
(108–
754)
1 in 45 
(18–
110)
1 in 787 
(333–
1859)
1 in 147 
(58–373)
1 in 730 
(308–
1728)
1 in 56 
(23–135)
1 in 462 
(181–1181)
p value 0.42 <0.001 0.01 <0.01
Enrichment 
factor (br/
dim)
1.79 17.49 4.97 8.25
Table 1. Limiting dilution assay for CD24, CD44, EpCAM and EpCAM/CD44 cells from xeno-B110 (first 
generation). ND, not determined.
Cell 
Inoculation 
number
Number of tumours/Number of inoculated mice
CD24 CD44 EpCAM
br dim br dim br dim
xeno-B110
500 3/3 1/3 3/3 2/3 3/3 2/3
100 5/6 2/6 4/6 1/5 4/6 1/6
10 1/6 0/6 2/6 0/6 0/6 0/6
Estimated TIC 
frequency (CI)
1 in 56 
(23–
135)
1 in 591 
(177–
1971)
1 in 67 
(27–
163)
1 in 474 
(149–
1511)
1 in 104 
(42–
261)
1 in 509 
(162–
1605)
p value <0.01 <0.01 0.03
Enrichment 
factor (br/dim) 10.55 7.07 4.89
Table 2. TIC frequency of CD24, CD44 and EpCAM cells from xeno-B110 at fourth generation.
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in EpCAMbr cells transduced with KLF4 lentiviral construct compared to EpCAMbr cells containing empty 
vector (Fig. 6a). Functionally, there was a decrease in growth for KLF4-overexpressed EpCAMbr cells compared 
to EpCAMbr cells with empty vector (Fig. 6c). Consistent with this, there was an increased expression of p21, a 
downstream transcriptional target of KLF4, in KLF4-overexpressed EpCAMbr cells compared to EpCAMbr cells 
with empty vector (Fig. 6b).
Viable non-mouse xeno-B110 cells were treated with 0, 1, 5 and 10 μM Kenpaullone, a chemical inhibitor 
against KLF4 and evaluated for in vitro proliferation at 1, 6, 24, 48 and 72 h post-treatment. At 6 h post-treatment, 
KLF4 mRNA was downregulated in Kenpaullone-treated cells in a dose-dependent manner compared to 
untreated cells (Fig. 6d). There was a corresponding increase of in vitro growth of these treated cells in com-
parison to untreated cells between 6 to 24 hours of treatment (Fig. 6e). At 24 h post-treatment, the transcripts 
level of KLF4 seemed to have reverted to baseline which was comparable to the untreated cells (Fig. 6d). Lower 
dose-treated cells displayed an increase in vitro growth over that of untreated cells, whilst 10 μM treated cells had 
a decrease in cell growth (Fig. 6e). Overall, transient KLF4 downregulation by Kenpaullone led to concurrent 
increase of in vitro growth.
Expression of selected transcripts and proteins in NPC specimens. Targeted RNA sequencing 
(RNA-seq) data was obtained from a prior study36 and reanalysed for specific transcripts using DESeq2 in 7 
non-NPC and 10 NPC specimens (1 from non-keratinising differentiated carcinoma and 9 from non-keratinising 
undifferentiated carcinoma). CD44 and EPCAM transcripts were significantly more than 2 folds upregulated in 
NPC compared to non-NPC specimens (p = 0.0001 for CD44 and p = 0.0004 for EPCAM) (Fig. 7a). CD24 was 
not analysed due to failure of optimal primer design for CD24 in this targeted RNA-seq. CD44 expression was 
heterogeneously seen in NPC stages 2 to 4 (Fig. 7b). On the other hand, EPCAM expression increased with dis-
ease stage, with Stage 4 C having the highest expression (Fig. 7c).
Due to more promising tumourigenicity data, stable TIC frequency during serial transplantation and inverse 
association with KLF4 mRNA level observed in EpCAMbr xeno-B110 cells, co-staining of EpCAM and KLF4 
proteins were performed in a separate set of 10 archival specimens (3 from non-keratinising undifferentiated 
carcinoma, 6 from non-keratinising differentiated carcinoma and 1 from keratinising squamous cell carcinoma). 
Likewise in xeno-B110 tumour FFPE sections, the brightest stained tumour cells (above 95th percentile) showed 
an inverse expression trend between the two proteins, i.e. high EpCAM and low KLF4 co-expressions, and 
vice-versa in the patient specimens (representative data in Fig. 7d-e).
Figure 4. Gene expression of CD24br, CD44br, EpCAMbr and EpCAM/CD44dbr cells from xeno-B110. 
(a) Fold changes of BMI1, MKI67, NANOG, OCT4A, SOX2, CD24, CD44 and EPCAM genes by RT-qPCR 
in ABI7500 FAST system. (b) Fold changes of CCND1, CCNE1, CDKN1A, CTNNB1, KLF4, MYC, NOTCH1 
and VIM genes by RT-qPCR in Fluidigm Biomark system. Results, (a) mean ± SEM of 3 sorted cell sample 
replicates, (b) mean ± SEM of 2 or 3 sorted cell sample replicates. *p < 0.05, **p < 0.01.
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Discussion
This study attempts to delineate the biological properties of NPC cells identified by three common CSC sur-
face markers concurrently within the same experiments. We first established that CD44br and EpCAMbr cells 
from both C666-1 cell line and xeno-B110 early-passage PDX consistently enriched for faster-growing tumour-
igenic cells which resulted in larger tumour growth, with more notable growth differences seen from xeno-B110 
marker-selected cells. There was a higher TIC content in CD44br and EpCAMbr cells of xeno-B110 in the first 
generation of marker-induced growth; however, combination of CD44br and EpCAMbr markers did not further 
enhance for faster-growing cells or cells with higher TIC frequency than CD44br marker alone. CD24br, CD44br 
and EpCAMbr cells could self-renew for at least four generations. KLF4 was consistently downregulated in all 
bright phenotype of CD24, EpCAM and EpCAM/CD44 cells of xeno-B110 and was shown to be anti-proliferative 
in our in vitro study. Finally, heterogeneous KLF4 and EpCAM co-expression patterns were observed in archival 
NPC specimens and increased EPCAM coincided with increasing disease stage.
EpCAM has been in use as a CSC marker in other solid tumours such as breast, colon and pancreatic can-
cers since 2000s37. Clinically, high expression of EpCAM was also notably associated with higher gastric carci-
noma cell proliferation and disease progression38. However, the role of EpCAM in NPC is still unclear. In our 
early-passage NPC PDX, xeno-B110, EpCAMbr marker identified for fast-growing cells with higher levels of 
stem cell related genes and had the ability to be passaged for at least four generations while maintaining its TIC 
frequency. Quantitative PCR and IF staining showed that EpCAMbr cells had lower KLF4 (KLF4) compared 
to EpCAMdim cells in our NPC xenograft. Immunofluorescence staining in archival NPC specimens revealed 
that subsets of tumour cells co-expressing high EpCAM and low KLF4 protein levels were also present in NPC 
patients. Current knowledge suggests that advanced cancers contain higher number of CSCs than early can-
cers39,40. Indeed, our targeted RNA-seq analysis showed that EpCAM transcripts were increased with advanced 
stage of NPC, thus strengthening our view that EpCAM is a putative CSC marker in NPC.
CD44 is amongst the most investigated CSC markers in NPC14. This surface marker has been mainly studied 
in NPC cell lines such as C666-1, SUNE-1 and CNE-18,26,41. The most striking differences between our study and 
currently available reports are i) our use of an early-passage NPC PDX as a study model, and ii) the evaluation 
of self-renewal ability which is central to (cancer) stem cell’s identity was assayed in vivo up to the fourth gener-
ation of serial transplantation. Our tumour initiation and in vivo growth data from CD44 xenografts of C666-1 
and xeno-B110 are in agreement with prior studies. Many investigations on CD44 and self-renewal ability were 
performed in in vitro with spheroid or colony-forming assays41–43, whereas, we demonstrated that CD44br cells 
could self-renew in vivo. Our findings revealed that CD44br cells were proliferative in nature consistent with 
remarkably high S-phase cell content and increased MKI67 mRNA transcript. There was a significant more than 
2-fold increase of CD44 transcript in NPC compared to non-NPC specimens in our study. However, we did not 
Figure 5. Co-expression of EpCAM with KLF4, p21 and cyclin D1 in xeno-B110. Representative images of 
EpCAM (CY5) co-stained with KLF4 (FITC), p21 (FITC) and cyclin D1 (FITC). 20X objective.
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see a consistent trend of an increase of CD44 in concurrence with lymph node involvement (data not shown) as 
reported in a prior study44.
CD24 as a CSC marker for NPC has received lesser attention than CD44. CD24+ was reported as a CSC phe-
notype in NPC cell lines TW02 and TW0427 while CD44highCD24low nasopharyngeal epithelial cells transfected 
with LMP1 showed the ability to form tumour spheres in vitro45. Nonetheless, CSC functionality i.e. in vivo 
self-renewal was not examined in both studies. Our findings revealed that CD24br cells showed slightly elevated 
level of VIM, a marker for cells undergoing EMT, and larger tumour growth that was not as marked as compared 
to other bright phenotypes. However, these CD24br cells could maintain tumour self-renewal ability in vivo for at 
least up to the fourth generation of serial transplantation and they warrant further investigations.
KLF4 is a transcription factor with known functions in pluripotency, tumour suppression or progression and 
cell differentiation46. There are a few lines of evidence in our study which imply that KLF4 has anti-proliferative 
effects in xeno-B110. CD24br, EpCAMbr and EpCAM/CD44dbr cells initiated larger xenograft growth, were 
more actively proliferating and had higher proportions of S-phase cells. These cells expressed decreased KLF4 
(mRNA and protein) compared to their respective dim cells. The effect of KLF4 on NPC cell proliferation was val-
idated by overexpression and inhibition studies. EpCAMbr cells of xeno-B110 which were transduced with KLF4 
proliferated much slower than EpCAMbr cells transduced with empty vector. Conversely, transient inhibition of 
KLF4 with Kenpaullone (a short acting inhibitor of KLF4 transcription47) in xeno-B110 cells indeed resulted in 
increased cell proliferation. The inverse relationship between KLF4 levels and cell proliferation seen in xeno-B110 
may be caused by the engagement of p53 by KLF4 to activate the transcription of CDKN1A gene which encodes 
p21, in turn leading to cell cycle arrest46.
Figure 6. Modulation of KLF4 in xeno-B110. Overexpression of KLF4 was performed in EpCAMbr cells with 
KLF4 lentiviral construct and compared to control (empty vector). Representative images of transduced cells 
stained with (a) KLF4, (b) p21 and DAPI, 20X objective. (c) Representative in vitro growth curves of transduced 
EpCAMbr cells. (d) KLF4 transcript levels at 6 and 24 hours after Kenpaullone treatment. (e) Representative in 
vitro growth curves of untreated and treated xeno- B110 cells. Results of growth curves, (c) mean ± SEM of 3 
replicate wells, (e) mean ± SEM of 2 replicate wells. Results of gene expression fold change, (d) mean ± SEM of 3 
sorted cell sample replicates.
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Figure 7. Expression of selected transcripts and proteins in non-NPC and NPC specimens. (a) RNA-seq data 
from non-NPC and NPC specimens were analysed for CD44 and EPCAM expression. (b) CD44 and (c) EPCAM 
expression was also individually analysed according to NPC disease staging. Results, median of 7 non-NPC 
or 10 NPC specimens for RNA-seq. (d) Co-staining of EpCAM and KLF4 in a patient specimen with non-
keratinising (NK) undifferentiated carcinoma (UDC). Scatter plot of mean fluorescence intensities for EpCAM 
and KLF4 shows cells with high EpCAM and low KLF4 co-expressions highlighted in red dotted box, and low 
EpCAM high KLF4 cells highlighted in green dotted box. Yellow arrow head shows representative tumour 
cells from red dotted box. White arrow head shows representative tumour cells from green dotted box. (e) Co-
staining of EpCAM and KLF4 in a patient specimen with non-keratinising (NK) differentiated carcinoma (DC). 
Scatter plot of mean fluorescence intensities for EpCAM and KLF4 shows cells with high EpCAM and low KLF4 
co-expressions highlighted in red dotted box, and low EpCAM high KLF4 cells highlighted in green dotted box. 
Representative cells from red and green dotted boxes are highlighted by white arrow head in the corresponding 
images. All images were captured using 20X objective. ***p < 0.001.
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CD24 positive and CD44 positive cells in HK1 was reported as 0.86% and 16.30%, respectively27. CD44 pos-
itivity in C666-1 ranged from 5% to approximately 45% in two independent studies8,48. We found that there was 
slightly more than 60% of CD24 positive and nearly 100% of CD44 positive cells in HK1, and more than 90% 
of CD44 positive cells in C666-1. The variations in immunophenotyping data between our study and others are 
believed to have arisen from technical differences such as culture conditions and enzymatic detachment, as well 
as gating strategy used to derive percentage of positive cells49,50.
In view of the limitation in long term cultured cell lines, early-passage PDX cells (passages 5 to 9) were 
used throughout our study to avoid losing the original identity and cellular features of the tumour24,51. The 
high tumourigenic ability (less cells needed to initiate tumour growth) seen in parental xeno-B110 cells may 
be explained by the probability of xeno-B110 itself being highly tumourigenic and the use of NSG mice in our 
study. Lacking functional natural killer (NK) cells in addition to mature T and B cells52, NSG mice provide highly 
efficient engraftment of exogenous cells as demonstrated by the seminal study of Quintana et al.53. The use of 
Matrigel as a co-inoculation agent in our study may have also improved tumour formation with as low as 100 
cells. The ability of such low number of cells to form tumours has been reported. A 5-cell inoculation of mela-
noma cells mixed with Matrigel and injected into NSG mice had a tumour formation efficiency of 39% (7/18)53, 
whereas 100 cells of Matrigel-mixed CD44+ subpopulation and CD44+CD24+ESA+ subpopulation from pancre-
atic cancer PDXs formed tumours at an efficiency of 25% (4/16) and 50% (6/12), respectively54.
Conclusion
In summary, CD44br and EpCAMbr cells from NPC cell line and early-passage PDX were fast-growing and more 
tumourigenic than their respective dim phenotype which resulted in larger tumours. However, the combination 
of CD44br and EpCAMbr markers did not further enrich for more fast-growing or tumourigenic cells. CD24br, 
CD44br and EpCAMbr cells from early-passage NPC PDX were also enriched for TIC and retained self-renewal 
property upon serial transplantation in vivo. The expression of EPCAM was negatively correlated with KLF4 
and CDKN1A, while KLF4 level was inversely associated with proliferation of NPC cells. Consistent with this, 
increased expression of EPCAM in NPC tumours was associated with more advanced stage of the disease. These 
suggest the importance of EpCAM in nasopharyngeal carcinoma.
Materials and methods
Ethics statements. All procedures and experimental protocols involving the use of NPC PDXs in this study were 
in accordance with the ethical standards of and approved by the Animal Care and Use Committee, Ministry of Health, 
Malaysia ((ACUC/KKM/02(3/2013) and ACUC/KKM/02(05/2016)). All procedures and experimental protocols 
involving the use of human specimens in this study were in accordance with the ethical standards of and approved 
by the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (KKM/NIHSEC/P11-524 and 
KKM/NIHSEC/P13-108). Informed consent was obtained from all participating human subjects for the collection of 
fresh tissue and blood specimens. The use of anonymised archival tissue blocks was approved by the MREC.
Cell lines and culture conditions. HK1 cells were cultured in RPMI-1640 medium containing 10% fetal 
calf serum and 1X penicillin/streptomycin (all from Gibco, USA) in 6-cm tissue culture plates (TPP, Switzerland). 
C666-1 cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum, 1X Glutamax and 
1X penicillin/streptomycin (all from Gibco, USA) in 10-cm tissue culture plates (BD Falcon, USA). Both cell 
lines were maintained in a 5% CO2 incubator at 37 °C. The cells were confirmed to be mycoplasma-free by peri-
odical testing with Venor GeM Mycoplasma Detection Kit for Conventional PCR (Minerva Biolabs, Germany). 
Authentication of the cell lines (short tandem repeat, STR, profiling) were performed using the AmpFLSTR 
Identifiler PCR Amplification Kit (Applied Biosystem, Life Technologies, USA).
Sample processing and staining for flow analyses or cell sorting. Freshly harvested xenografts 
(xeno-284 and xeno-B110) were digested and single cell suspensions of NPC cell lines and xenografts were 
stained and analysed or sorted in BD FACSAria SORP (BD Biosciences, USA).
In vivo tumourigenicity. Four to 6 weeks old female NOD-scid gamma (NSG) mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ; The Jackson Laboratory, USA) were used for endpoint experiments to measure tumour latency, 
growth curve and for calculation of mitotic figures with marker-selected C666-1 and xeno-B110 cells. Serial 
transplantation was also performed with marker-selected xeno-B110 cells.
Detailed protocols (above and others) are available in Supplementary Methods.
Statistical analysis. Unpaired t-test was applied for mean latency, paired t-test for cell cycle and RT-qPCR, 
and Mann Whitney U-test for adjusted MAI, presence of necrosis and/or stroma and RNA-seq data using 
GraphPad Prism (version 6.0; GraphPad Software, Inc., USA). Significance was defined at the p < 0.05, p < 0.01 
or p < 0.001 level as indicated in each figure description. Error bars represent mean ± SD or SEM as indicated in 
each figure description. TIC frequency was analysed according to Extreme Limiting Dilution Analysis (ELDA)55.
Data availability. The dataset that supports the findings of RNA sequencing are available from Ching-Ching 
Ng upon reasonable request.
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